|
[Related PubMed/MEDLINE] Total Number of Papers: 76
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. |
RCB, TIL |
2 |
2020 |
Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy. |
CTBS |
3 |
2020 |
Radiotherapy after primary CHEMotherapy (RAPCHEM): Practice variation in a Dutch registration study (BOOG 2010-03). |
BC, RAPCHEM, RT, SG |
4 |
2019 |
Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning. |
BCS, MRI, pCR, TN |
5 |
2019 |
Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy. |
CADM, TNBC |
6 |
2019 |
Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. |
SNB |
7 |
2019 |
When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy? |
BCSS, DM, LRR, LVI, OS, PMRT |
8 |
2018 |
Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. |
ER, HER2, PR |
9 |
2018 |
Primary medical therapy and breast conservation treatment: the medical oncology perspective. |
AST, pCR |
10 |
2018 |
Shear Wave Speed of the Lesion in Preoperative Breast Ultrasonography: Association with Disease-free Survival of Patients with Primary Operable Invasive Breast Cancer. |
CI, HR, SWS, US |
11 |
2018 |
Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST). |
CI, ER, OR |
12 |
2018 |
Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. |
AUC, OR, SLN |
13 |
2017 |
Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. |
CT, ET, OS, OSCT |
14 |
2017 |
Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer. |
pCR |
15 |
2016 |
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. |
HER2, OS, pCR, RFS |
16 |
2016 |
The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement. |
BCS, RT, SNB |
17 |
2015 |
Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results. |
EORTC, LI, PERCIST, RECIST, WHO |
18 |
2015 |
MRI and ultrasound evaluation of invasive lobular carcinoma of the breast after primary systemic therapy. |
BCS, ILC, MRI, US |
19 |
2015 |
Oncological safety of breast-conserving surgery after primary systemic chemotherapy in cT3-4 breast cancer patients. |
BCS, LR, LRFS |
20 |
2015 |
Patterns of practice of regional nodal irradiation in breast cancer: results of the European Organization for Research and Treatment of Cancer (EORTC) NOdal Radiotherapy (NORA) survey. |
ALND, BC, BCS, ECE, EORTC, IMC, NORA, RNI, RT, SCN, SLN, TM |
21 |
2015 |
Personalization of loco-regional care for primary breast cancer patients (part 1). |
--- |
22 |
2015 |
Personalization of loco-regional care for primary breast cancer patients (part 2). |
--- |
23 |
2015 |
Primary systemic therapy for breast cancer: Does the patient's involvement in decision-making create a new future? |
LABC |
24 |
2015 |
Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study. |
CR, HER2, NPV, pCR, sens, SPEC |
25 |
2015 |
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients. |
HER2, pCR |
26 |
2014 |
Photoacoustic mammography: initial clinical results. |
DCIS, IBC, MRI, PAM |
27 |
2014 |
Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients. |
BM, DTC |
28 |
2013 |
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). |
HER2, pCR |
29 |
2013 |
Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy. |
CR, DFS, DTC, LABC, OS |
30 |
2013 |
The detection of pCR after PST by contrast-enhanced ultrasonography for breast cancer. |
CEUS, pCR |
31 |
2013 |
The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer. |
Cx, TMA |
32 |
2013 |
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. |
BCSC, EMT, pCR, TILs |
33 |
2012 |
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. |
--- |
34 |
2012 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review. |
--- |
35 |
2011 |
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. |
CSC |
36 |
2011 |
Breast cancer and primary systemic therapy. Results of the Consensus Meeting on the recommendations for pathological examination and histological report of breast cancer specimens in the Marche Region. |
--- |
37 |
2011 |
Feasibility of sentinel lymph node biopsy in breast cancer patients with initial axillary lymph node metastasis after primary systemic therapy. |
ALN, ALND, AUS, CR, SLNB |
38 |
2011 |
Intermediate endpoints of primary systemic therapy in breast cancer patients. |
--- |
39 |
2011 |
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). |
pCR |
40 |
2011 |
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. |
CI, HER2, LTFU, OS, RFS |
41 |
2011 |
[Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status]. |
DTX, EC, ER, HR, pCR, PgR, PTX |
42 |
2010 |
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. |
5-FU, DT, LABC, OS, pCR, RFS |
43 |
2010 |
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. |
pCR |
44 |
2010 |
Sentinel lymph node biopsy is precise after primary systemic therapy in stage II-III breast cancer patients. |
ALND, SLNB |
45 |
2008 |
Changes in tumour biological markers during primary systemic chemotherapy (PST). |
Bcl-2, ER, PR |
46 |
2008 |
Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer. |
CR, EC |
47 |
2008 |
High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. |
ER, ORR |
48 |
2008 |
Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. |
BHGI, LABC |
49 |
2008 |
Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. |
cCR |
50 |
2008 |
Primary systemic therapy in breast cancer: past lessons and new approaches. |
pCR |
51 |
2008 |
Prognostic value of initial clinical disease stage after achieving pathological complete response. |
IBC, OS, pCR, RFS |
52 |
2008 |
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. |
--- |
53 |
2008 |
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. |
HER2, pCR |
54 |
2007 |
Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial. |
pCR |
55 |
2007 |
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. |
CI, pCR |
56 |
2006 |
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. |
LABC, mRNA |
57 |
2006 |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. |
DOC, pCR |
58 |
2006 |
Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. |
pCR |
59 |
2006 |
Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. |
--- |
60 |
2006 |
Primary systemic therapy of breast cancer. |
pCR |
61 |
2006 |
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? |
IHC, NK |
62 |
2006 |
[Clinical usefulness of MD-CT]. |
BCS, EIC |
63 |
2006 |
[Primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]. |
LABC |
64 |
2005 |
Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. |
PgR |
65 |
2005 |
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma. |
LABC, pCR |
66 |
2005 |
Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. |
pCR |
67 |
2005 |
Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. |
IBC |
68 |
2005 |
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. |
FAC, pCR |
69 |
2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study. |
DLTs, MTD, pCR |
70 |
2004 |
Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. |
MR |
71 |
2004 |
[Neoadjuvant therapy of breast cancer]. |
--- |
72 |
2003 |
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. |
--- |
73 |
2003 |
Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combination. |
--- |
74 |
2002 |
Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. |
LABC |
75 |
2000 |
Early operable breast cancer. |
BCT |
76 |
2000 |
Primary systemic therapy in operable breast cancer. |
BCT, DFS, OS, RCTs |
|